Work

First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4591

Authors: Brigida Anna Maiorano, Joep de Jong, James A. Proudfoot, Giuseppe Basile, Antonio Cigliola, Valentina Tateo, Chiara Mercinelli, Elai Davicioni, Marco Moschini, Michela Ravasi, Giorgio Brembilla, Maurizio Colecchia, Francesco De Cobelli, Alberto Briganti, Francesco Montorsi, Andrea Necchi

Institutions: IRCCS Ospedale San Raffaele, Erasmus MC, Veracyte (United States), Vita-Salute San Raffaele University, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822185

Cites:

Cited by: 6

Related to: 10